Zimmer Biomet Holdings, Inc. (ZBH) Covered Calls

Zimmer Biomet Holdings, Inc. is a global leader in musculoskeletal healthcare, specializing in the design, manufacture, and marketing of orthopedic reconstructive products, sports medicine, biologics, extremities, trauma products, and surgical/robotic technologies. The company is dedicated to alleviating pain and restoring mobility for patients suffering from joint conditions or musculoskeletal injuries.

You can sell covered calls on Zimmer Biomet Holdings, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ZBH (prices last updated Wed 3:30 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Zimmer Biomet (ZBH) operates as a critical partner in the medical technology ecosystem, focusing on the high-barrier orthopedic market. Its business model is built on deep, long-standing relationships with orthopedic surgeons and healthcare institutions, who rely on the company’s extensive portfolio of joint replacement implants (knees, hips, shoulders) and advanced surgical instrumentation. Beyond its core implants, ZBH is aggressively pivoting toward a technology-integrated model, leveraging its ZBEdge platform and ROSA robotic systems to provide surgeons with real-time data, navigation, and precision assistance during complex procedures.

The company’s growth is anchored in a continuous product innovation cycle—often referred to internally as the "Magnificent Seven"—which aims to capture market share through differentiated clinical outcomes. By focusing on musculoskeletal "continuum of care" solutions, ZBH captures revenue across the surgical and post-operative recovery phases, positioning itself as a vertically integrated provider in a highly regulated, oligopolistic market characterized by high switching costs and robust institutional demand.

Competitive Landscape

Zimmer Biomet competes in the capital-intensive and highly regulated orthopedic medical device sector. Its primary optionable peers include:

1. Stryker Corporation (SYK): The preeminent competitor in robotic-assisted surgery (Mako) and orthopedics, setting the industry benchmark for operational execution and innovation.
2. Johnson & Johnson (JNJ): Through its DePuy Synthes division, J&J competes with massive scale, financial power, and a comprehensive portfolio of orthopedic and trauma solutions.
3. Medtronic plc (MDT): A diversified healthcare giant that competes in various surgical technologies, instrumentation, and musculoskeletal-adjacent markets.
4. Boston Scientific Corporation (BSX): While more focused on cardiovascular and interventional medicine, it competes in the broader high-growth medical technology space for institutional capital and surgeon mindshare.

Strategic Outlook and Innovation

ZBH’s strategic outlook is defined by its operational turnaround efforts and a shift toward higher-growth robotic and digital surgery segments. The company is currently undergoing a U.S. sales force transformation to increase focus and specialization, aimed at driving long-term organic growth. Innovation is centered on "smart" implants (like the Persona IQ) and AI-driven navigation tools (ROSA), which represent the future of personalized, evidence-based surgery.

By investing in proprietary process design and data analytics, ZBH seeks to move beyond being a hardware vendor to becoming an intelligence-driven surgical partner. As the aging global population continues to drive demand for joint reconstruction, the company’s ability to successfully execute its pipeline—specifically in robotic-assisted shoulder and knee replacements—will be the primary determinant of its ability to narrow the valuation gap with its peers.

Want more examples? Z Covered Calls | ZBIO Covered Calls